Skip to main content
. 2012 Sep 12;2012(9):CD009157. doi: 10.1002/14651858.CD009157.pub2

Geitona 2011.

Methods A cost‐utility and a cost‐effectiveness analysis based on a Markov model, for the Greek NHS
Participants Patients with COPD
Interventions Indacaterol versus tiotropium or formoterol
Outcomes QALYs, life years gained (LYG) and exacerbation rates, cost
Notes